Trials / Recruiting
RecruitingNCT07091526
Whether Control of Serum Uric Acid (SUA) Improves Survival After Pancreatic Cancer
Whether Controlling Serum Uric Acid (SUA) Can Benefit Postoperative Survival in Patients With Pancreatic Cancer
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 168 (estimated)
- Sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This retrospective study aims to analyze the impact of postoperative changes in serum uric acid (SUA) levels on the prognosis of patients undergoing pancreatic cancer resection.
Detailed description
Serum uric acid is a risk factor for gallbladder cancer in men and has a strong effect on pancreatic cancer in women. It has also been shown that elevated intracellular serum uric acid can induce an inflammatory stress response, which may promote its transformation, while elevated extracellular serum uric acidy further stimulate tumor cell proliferation, migration, and survival, and promote the development of highly aggressive cancer. In this study, the changes of serum uric acid before and after surgery was used as a prognostic marker for the survival of pancreatic cancer patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | serum uric acid test | Detect the serum uric acid in blood sample |
Timeline
- Start date
- 2025-07-29
- Primary completion
- 2026-12-29
- Completion
- 2026-12-29
- First posted
- 2025-07-29
- Last updated
- 2025-12-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07091526. Inclusion in this directory is not an endorsement.